[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fWlhOmWVs1g_eAEQFFsTG82HPjwNyueLu9M1c3hr9MPY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"LMC Diabetes & Endocrinology Ltd.",[4],21,false,4,0,23929,1,13,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Type 2 Diabetes",7,{"name":18,"count":19},"Diabetes Mellitus, Type 1",3,{"name":21,"count":19},"Diabetes Mellitus, Type 2",{"name":23,"count":24},"Type 2 Diabetes Mellitus",2,{"name":26,"count":24},"Diabetes Mellitus",{"name":28,"count":11},"Nonalcoholic Steatohepatitis",{"name":30,"count":11},"Type2 Diabetes",{"name":32,"count":11},"Chronic Kidney Diseases",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT07424430","Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes","2026-04","Semaglutide",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,81,107,125,143,168,186,212,230,248,275,301,319,337,362],{"intervention":38,"totalTrials":24,"cells":48},{"EARLY_PHASE1":49,"PHASE1":51,"PHASE2":53,"PHASE3":55,"PHASE4":57,"NA":59},{"trials":50,"activeCount":9},[],{"trials":52,"activeCount":9},[],{"trials":54,"activeCount":9},[],{"trials":56,"activeCount":9},[],{"trials":58,"activeCount":9},[],{"trials":60,"activeCount":11,"soonestReadout":37},[61,71],{"nctId":62,"briefTitle":63,"status":64,"phases":65,"primaryCompletion":66,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":70},"NCT04175665","Real-world Health Outcomes in Canadian Patients Using Semaglutide","COMPLETED",[],"2020-02-09","2020-01-06",1133,[15],[38],{"nctId":35,"briefTitle":36,"status":72,"phases":73,"primaryCompletion":37,"completion":74,"start":75,"enrollment":76,"conditions":77,"interventions":80},"NOT_YET_RECRUITING",[],"2026-05","2026-03",400,[78,15,79],"Diabetes (DM)","Obesity (Disorder)",[38],{"intervention":82,"totalTrials":11,"cells":83},"DPP-4 inhibitor",{"EARLY_PHASE1":84,"PHASE1":86,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":105},{"trials":85,"activeCount":9},[],{"trials":87,"activeCount":9},[],{"trials":89,"activeCount":9},[],{"trials":91,"activeCount":9},[],{"trials":93,"activeCount":9},[94],{"nctId":95,"briefTitle":96,"status":97,"phases":98,"primaryCompletion":99,"completion":99,"start":100,"enrollment":9,"conditions":101,"interventions":102},"NCT03813316","Approaches To Therapy Escalation In T2D","WITHDRAWN",[44],"2019-09-18","2019-05-01",[30],[82,103,104],"SGLT2 inhibitor","SGLT2 inhibitor and DPP-4 inhibitor",{"trials":106,"activeCount":9},[],{"intervention":103,"totalTrials":11,"cells":108},{"EARLY_PHASE1":109,"PHASE1":111,"PHASE2":113,"PHASE3":115,"PHASE4":117,"NA":123},{"trials":110,"activeCount":9},[],{"trials":112,"activeCount":9},[],{"trials":114,"activeCount":9},[],{"trials":116,"activeCount":9},[],{"trials":118,"activeCount":9},[119],{"nctId":95,"briefTitle":96,"status":97,"phases":120,"primaryCompletion":99,"completion":99,"start":100,"enrollment":9,"conditions":121,"interventions":122},[44],[30],[82,103,104],{"trials":124,"activeCount":9},[],{"intervention":104,"totalTrials":11,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":141},{"trials":128,"activeCount":9},[],{"trials":130,"activeCount":9},[],{"trials":132,"activeCount":9},[],{"trials":134,"activeCount":9},[],{"trials":136,"activeCount":9},[137],{"nctId":95,"briefTitle":96,"status":97,"phases":138,"primaryCompletion":99,"completion":99,"start":100,"enrollment":9,"conditions":139,"interventions":140},[44],[30],[82,103,104],{"trials":142,"activeCount":9},[],{"intervention":144,"totalTrials":11,"cells":145},"Colesevelam",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":166},{"trials":147,"activeCount":9},[],{"trials":149,"activeCount":9},[],{"trials":151,"activeCount":9},[],{"trials":153,"activeCount":9},[],{"trials":155,"activeCount":9},[156],{"nctId":157,"briefTitle":158,"status":64,"phases":159,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":164},"NCT02682680","Randomized Trial Comparing Colesevelam vs. Ezetimibe",[44],"2017-05-25","2016-01-11",200,[23],[144,165],"Ezetimibe",{"trials":167,"activeCount":9},[],{"intervention":165,"totalTrials":11,"cells":169},{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":184},{"trials":171,"activeCount":9},[],{"trials":173,"activeCount":9},[],{"trials":175,"activeCount":9},[],{"trials":177,"activeCount":9},[],{"trials":179,"activeCount":9},[180],{"nctId":157,"briefTitle":158,"status":64,"phases":181,"primaryCompletion":160,"completion":160,"start":161,"enrollment":162,"conditions":182,"interventions":183},[44],[23],[144,165],{"trials":185,"activeCount":9},[],{"intervention":187,"totalTrials":11,"cells":188},"Basal insulin glargine and lixisenatide",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":210},{"trials":190,"activeCount":9},[],{"trials":192,"activeCount":9},[],{"trials":194,"activeCount":9},[],{"trials":196,"activeCount":9},[],{"trials":198,"activeCount":9},[199],{"nctId":200,"briefTitle":201,"status":64,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT03819790","The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians",[44],"2019-11-19","2018-10-02",119,[21],[187,208,209],"Basal insulin Basaglar\u002FLantus + gliclazide MR","Metformin",{"trials":211,"activeCount":9},[],{"intervention":208,"totalTrials":11,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":9},[],{"trials":217,"activeCount":9},[],{"trials":219,"activeCount":9},[],{"trials":221,"activeCount":9},[],{"trials":223,"activeCount":9},[224],{"nctId":200,"briefTitle":201,"status":64,"phases":225,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":226,"interventions":227},[44],[21],[187,208,209],{"trials":229,"activeCount":9},[],{"intervention":209,"totalTrials":11,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":9},[],{"trials":235,"activeCount":9},[],{"trials":237,"activeCount":9},[],{"trials":239,"activeCount":9},[],{"trials":241,"activeCount":9},[242],{"nctId":200,"briefTitle":201,"status":64,"phases":243,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":244,"interventions":245},[44],[21],[187,208,209],{"trials":247,"activeCount":9},[],{"intervention":249,"totalTrials":11,"cells":250},"Insulin Degludec",{"EARLY_PHASE1":251,"PHASE1":253,"PHASE2":255,"PHASE3":257,"PHASE4":259,"NA":273},{"trials":252,"activeCount":9},[],{"trials":254,"activeCount":9},[],{"trials":256,"activeCount":9},[],{"trials":258,"activeCount":9},[],{"trials":260,"activeCount":9},[261],{"nctId":262,"briefTitle":263,"status":264,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT03838783","Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered","UNKNOWN",[44],"2019-04-30","2019-06-30","2018-05-15",30,[271],"Type 1 Diabetes Mellitus",[249],{"trials":274,"activeCount":9},[],{"intervention":276,"totalTrials":11,"cells":277},"50% bolus insulin correction",{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":299},{"trials":279,"activeCount":9},[],{"trials":281,"activeCount":9},[],{"trials":283,"activeCount":9},[],{"trials":285,"activeCount":9},[],{"trials":287,"activeCount":9},[288],{"nctId":289,"briefTitle":290,"status":264,"phases":291,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":296},"NCT03057470","Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT)",[44],"2017-03","2016-05",18,[18],[276,297,298],"100% bolus insulin correction","150% bolus insulin correction",{"trials":300,"activeCount":9},[],{"intervention":297,"totalTrials":11,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":317},{"trials":304,"activeCount":9},[],{"trials":306,"activeCount":9},[],{"trials":308,"activeCount":9},[],{"trials":310,"activeCount":9},[],{"trials":312,"activeCount":9},[313],{"nctId":289,"briefTitle":290,"status":264,"phases":314,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":315,"interventions":316},[44],[18],[276,297,298],{"trials":318,"activeCount":9},[],{"intervention":298,"totalTrials":11,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":9},[],{"trials":324,"activeCount":9},[],{"trials":326,"activeCount":9},[],{"trials":328,"activeCount":9},[],{"trials":330,"activeCount":9},[331],{"nctId":289,"briefTitle":290,"status":264,"phases":332,"primaryCompletion":292,"completion":292,"start":293,"enrollment":294,"conditions":333,"interventions":334},[44],[18],[276,297,298],{"trials":336,"activeCount":9},[],{"intervention":338,"totalTrials":11,"cells":339},"GLP-1 receptor agonist",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":341,"activeCount":9},[],{"trials":343,"activeCount":9},[],{"trials":345,"activeCount":9},[],{"trials":347,"activeCount":9},[],{"trials":349,"activeCount":9},[],{"trials":351,"activeCount":9},[352],{"nctId":353,"briefTitle":354,"status":64,"phases":355,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},"NCT06236672","Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease",[],"2023-11-29","2023-02-15",348,[15,32],[338,361],"basal insulin",{"intervention":361,"totalTrials":11,"cells":363},{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":374},{"trials":365,"activeCount":9},[],{"trials":367,"activeCount":9},[],{"trials":369,"activeCount":9},[],{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[],{"trials":375,"activeCount":9},[376],{"nctId":353,"briefTitle":354,"status":64,"phases":377,"primaryCompletion":356,"completion":356,"start":357,"enrollment":358,"conditions":378,"interventions":379},[],[15,32],[338,361]]